Most-cited articles · 2020

The 50 most-cited articles in Value in Health, 2020

Ranked by OpenAlex citation count on 29 October 2026, out of 867 eligible articles Value in Health published in 2020. Ranks are frozen; this page will not change. Number one, with 205 citations: Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Cohort
867 articles
Listed
Top 50 (5.8%)
Open access
50 of 50
Snapshot
2026-10-29

The most-cited Value in Health articles of 2020 cluster around a few dominant themes: value of information and research prioritization methods, systematic reviews of care delivery and patient flow, and patient engagement and real-world evidence. The top paper, "Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force" by Fenwick, Steuten, Knies and colleagues, has 205 citations. Other highly cited works address lean healthcare, patient engagement in research, and partitioned survival models in oncology.

Readers can use this list to see which topics attracted the most citation attention in the journal that year. The entries span methodological guidance, systematic reviews, and policy analyses, and each is linked to its authors and citation count.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 2
    top 0.3%

    Effects of Lean Healthcare on Patient Flow: A Systematic Review

    Diego Tlapa, Carlos Zepeda-Lugo, Guilherme Luz Tortorella, Yolanda Angelica Baez-Lopez, Jorge Limón-Romero and 2 more

    179 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.11.002OpenAlex

    Show abstract

    OBJECTIVES: To assess the effects of lean healthcare (LH) on patient flow in ambulatory care and determine whether waiting time and length of stay (LOS) decrease after LH interventions. METHODS: A systematic review was performed with close adherence to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched for studies of healthcare organizations applying LH interventions within ambulatory care published between 2002 and 2018. Six databases and grey literature sources were used. Two reviewers independently screened and assessed each study. When consensus was difficult to reach, a third reviewer intervened. Finally, a summary of findings was generated. RESULTS: Out of 5627 studies, 40 were included. Regarding LOS for all patients, 19 out of 22 studies reported a decrease. LOS for discharged patients decreased in 11 out of 13 studies, whereas LOS for admitted patients was reduced in 6 out of 7 studies. Waiting time for patients before seeing a healthcare professional decreased in 24 out of 26 studies. Waiting time to treatment and waiting time for…

  2. 3
    top 0.4%

    Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group

    Rachel L. Harrington, Maya Hanna, Elisabeth M. Oehrlein, Rob Camp, Russell Wheeler and 8 more

    172 citationsOpen accessdoi:10.1016/j.jval.2020.01.019OpenAlex

  3. 4
    top 0.5%

    Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?

    Beth S. Woods, Eleftherios Sideris, Stephen Palmer, Nicholas R. Latimer, Marta O. Soares

    152 citationsOpen accessdoi:10.1016/j.jval.2020.08.2094OpenAlex

  4. 5
    top 0.6%

    Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

    Claire Rothery, Mark Strong, Hendrik Koffijberg, Anirban Basu, Salah Ghabri and 5 more

    130 citationsOpen accessdoi:10.1016/j.jval.2020.01.004OpenAlex

  5. 6
    top 0.7%

    Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review

    Ana Paula Beck da Silva Etges, Karen Brasil Ruschel, Carísi Anne Polanczyk, Richard D. Urman

    129 citationsOpen accessdoi:10.1016/j.jval.2020.02.004OpenAlex

  6. 8
    top 1%

    Distributional Cost-Effectiveness Analysis Comes of Age

    Richard Cookson, Susan C. Griffin, Ole Frithjof Norheim, Anthony J. Culyer, Kalipso Chalkidou

    121 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.001OpenAlex

    Show abstract

    Distributional cost-effectiveness analysis (DCEA) provides information about the equity impacts of health technologies and programs and the trade-offs that sometimes arise between equity and efficiency. This field has now come of age with a growing applied literature,1 new training resources,2 and a formal professional network: a special interest group on equity-informative economic evaluation within the International Health Economics Association.3

  7. 9
    top 1.1%

    Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

    Bruce A. Feinberg, Ajeet Gajra, Marjorie E. Zettler, Todd D. Phillips, Eli G. Phillips and 1 more

    121 citationsOpen accessdoi:10.1016/j.jval.2020.06.006OpenAlex

  8. 10
    top 1.2%

    Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary

    Fanni Rencz, Valentin Brodszky, László Gulàcsi, Dominik Golicki, G Ruzsa and 3 more

    115 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.03.019OpenAlex

    Show abstract

    OBJECTIVES: The wording of the Hungarian EQ-5D-3L and EQ-5D-5L descriptive systems differ a great deal. This study aimed to (1) develop EQ-5D-3L and EQ-5D-5L value sets for Hungary from a common sample, and (2) compare how level wording affected valuations. METHODS: In 2018 to 2019, 1000 respondents, representative of the Hungarian general population, completed composite time trade-off tasks. Pooled heteroscedastic Tobit models were used to estimate value sets. Value set characteristics, single-level transition utilities from adjacent corner health states, and mean transition utilities for all possible health states were compared between the EQ-5D-3L and EQ-5D-5L. RESULTS: Health utilities ranged from -0.865 to 1 for the EQ-5D-3L and -0.848 to 1 for the EQ-5D-5L. The relative importance of the 5 EQ-5D-5L dimensions was as follows: mobility, pain/discomfort, self-care, anxiety/depression, and usual activities. A similar preference ranking was observed for the EQ-5D-3L with self-care being more important than pain/discomfort. The EQ-5D-5L demonstrated lower ceiling effects (range of…

  9. 11
    top 1.3%

    Managed Entry Agreements: Policy Analysis From the European Perspective

    Monique Dabbous, Lylia Chachoua, Aleksandra Caban, Mondher Toumi

    113 citationsOpen accessdoi:10.1016/j.jval.2019.12.008OpenAlex

  10. 14
    top 1.7%

    Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis

    Adrienne Y L Chan, Vivien Kin Yi Chan, Sten Olsson, Min Fan, Mark Jit and 13 more

    103 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.06.020OpenAlex

    Show abstract

    OBJECTIVES: Three hundred million people living with rare diseases worldwide are disproportionately deprived of in-time diagnosis and treatment compared with other patients. This review provides an overview of global policies that optimize development, licensing, pricing, and reimbursement of orphan drugs. METHODS: Pharmaceutical legislation and policies related to access and regulation of orphan drugs were examined from 194 World Health Organization member countries and 6 areas. Orphan drug policies (ODPs) were identified through internet search, emails to national pharmacovigilance centers, and systematic academic literature search. Texts from selected publications were extracted for content analysis. RESULTS: One hundred seventy-two drug regulation documents and 77 academic publications from 162 countries/areas were included. Ninety-two of 200 countries/areas (46.0%) had documentation on ODPs. Thirty-four subthemes from content analysis were categorized into 6 policy themes, namely, orphan drug designation, marketing authorization, safety and efficacy requirements, price…

  11. 15
    top 1.8%

    Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review

    Anton L.V. Avanceña, Lisa A. Prosser

    84 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.010OpenAlex

    Show abstract

    OBJECTIVE: This systematic review aims to catalogue and describe published applications of equity-informative cost-effectiveness analysis (CEAs). METHODS: Following PRISMA guidelines, we searched Medline for English-language, peer-reviewed CEAs published on or before August 2019. We included CEAs that evaluated 2 or more alternatives; explicitly mentioned equity as a consideration or decision-making principle; and applied an equity-informative CEA method to analyze or examine at least 1 equity criterion in an applied CEA. We extracted data on selected characteristics and analyzed reporting quality using the CHEERS checklist. RESULTS: Fifty-four articles identified through a search and bibliography reviews met the inclusion criteria. All articles were published on or after 2010, with 80% published after 2015. Most studies evaluated primary prevention interventions in disease areas such as cancer, infectious diseases, and cardiovascular disease. Equity impact analysis alone was the most common equity-informative CEA (56%), followed by equity impact analysis with financial protection…

  12. 16
    top 1.9%

    Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey

    Joanna C. Thorn, Charlotte F. Davies, SARA T. BROOKES, Sian Noble, Melina Dritsaki and 9 more

    70 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.002OpenAlex

    Show abstract

    OBJECTIVES: Health economics analysis plans (HEAPs) currently lack consistency, with uncertainty surrounding appropriate content. We aimed to develop a list of essential items that should be included in HEAPs for economic evaluations conducted alongside randomized trials. METHODS: A list of potential items for inclusion was developed by examining existing HEAPs. An electronic Delphi survey was conducted among professional health economists. Respondents were asked to rate potential items from 1 (least important) to 9 (most important), suggest additional items, and comment on proposed items (round 1). A second survey (round 2) was emailed to participants, including the participant's own scores from round 1 along with summary results from the whole panel; participants were asked to rerate each item. Consensus criteria for inclusion in the final list were predefined as >70% of participants rating an item 7-9 and <15% rating it 1-3 after round 2. A final item selection meeting was held to scrutinize the results and adjudicate on items lacking consensus. RESULTS: 62 participants completed…

  13. 18
    top 2.1%

    Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods

    Natalia Kunst, Ed Wilson, David Glynn, Fernando Alarid‐Escudero, Gianluca Baio and 9 more

    66 citationsOpen accessdoi:10.1016/j.jval.2020.02.010OpenAlex

  14. 19
    top 2.2%

    Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

    Rick A. Vreman, Aukje Kaija Mantel-Teeuwisse, Anke Marijn Hövels, Hubert G. M. Leufkens, Wim Goettsch

    64 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.07.017OpenAlex

    Show abstract

    BACKGROUND: Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or procedures, which are known as HTA practices. OBJECTIVE: To provide insight into the effects of differences in practices on interpretation of intercountry differences in HTA recommendations for conditionally approved drugs. METHODS: HTA recommendations for conditionally approved drugs (N = 27) up until June 2017 from England/Wales, France, Germany, the Netherlands, and Scotland were included. Recommendations and practice characteristics were extracted from these five jurisdictions and this data was validated. The effect of nonsubmissions, resubmissions, and reassessments; cost-effectiveness assessments; and price negotiations on changes in the percentage of negative recommendations and the interpretation of intercountry differences in HTA outcomes were analyzed using Fisher exact…

  15. 20
    top 2.4%

    A Systematic Review of Economic Evaluations Reporting the Cost-Effectiveness of Spinal Cord Stimulation

    Siwaporn Niyomsri, Rui V. Duarte, Sam S. Eldabe, Gregory J. Fiore, Brian Harris Kopell and 2 more

    63 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.02.005OpenAlex

    Show abstract

    OBJECTIVES: Spinal cord stimulation (SCS) is a recognized treatment for chronic pain. This systematic review aims to assess economic evaluations of SCS for the management of all chronic pain conditions, summarize key findings, and assess the quality of studies to inform healthcare resource allocation decisions and future research. METHODS: Economic evaluations were identified by searching general medical and economic databases complemented with screening of reference lists of identified studies. No restrictions on language or treatment comparators were applied. Relevant data were extracted. The quality of included studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. RESULTS: Fourteen studies met the inclusion criteria and were judged to be of acceptable quality. Economic evaluations assessed SCS for the management of refractory angina pectoris, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), diabetic peripheral neuropathy (DPN), and peripheral arterial disease. Model-based studies typically applied…

  16. 22
    top 2.6%

    Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling

    Deborah Anne Marshall, Luiza Raquel Grazziotin, Dean A. Regier, Sarah Wordsworth, James Buchanan and 2 more

    59 citationsOpen accessdoi:10.1016/j.jval.2020.01.016OpenAlex

  17. 23
    top 2.7%

    Announcing the New Definition of Health Technology Assessment

    Brian P. O’Rourke, Wija Oortwijn, Tara Schuller

    58 citationsOpen accessdoi:10.1016/j.jval.2020.05.001OpenAlex

  18. 25
    top 2.9%

    Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index

    Anju Devianee Keetharuth, Donna Rowen, Jakob Bue Bjørner, John Edward Brazier

    56 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.10.012OpenAlex

    Show abstract

    BACKGROUND: There are increasing concerns about the appropriateness of generic preference-based measures to capture health benefits in the area of mental health. OBJECTIVES: The aim of this study is to estimate preference weights for a new measure, Recovering Quality of Life (ReQoL-10), to better capture the benefits of mental healthcare. METHODS: Psychometric analyses of a larger sample of mental health service users (n = 4266) using confirmatory factor analyses and item response theory were used to derive a health state classification system and inform the selection of health states for utility assessment. A valuation survey with members of the UK public representative in terms of age, sex, and region was conducted using face-to-face interviewer administered time-trade-off with props. A series of regression models were fitted to the data and the best performing model selected for the scoring algorithm. RESULTS: The ReQoL-Utility Index (UI) classification system comprises 6 mental health items and 1 physical health item. Sixty-four health states were valued by 305 participants. The…

  19. 26
    top 3%

    The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program

    Mónica Hernández Alava, Stephen E. Pudney, Allan Wailoo

    56 citationsOpen accessdoi:10.1016/j.jval.2019.10.017OpenAlex

  20. 28
    top 3.3%

    Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols

    Edward Henry, Luke E. Barry, Anna P. Hobbins, Nathan S. McClure, Ciarán O’Neill

    54 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.03.003OpenAlex

    Show abstract

    OBJECTIVES: To estimate and compare the minimally important difference (MID) in index score of country-specific EQ-5D-5L scoring algorithms developed using EuroQol Valuation Technology protocol version 2, including algorithms from Germany, Indonesia, Ireland, Malaysia, Poland, Portugal, Taiwan, and the United States. METHODS: A simulation-based approach contingent on all single-level transitions defined by the EQ-5D-5L descriptive system was used to estimate the MID for each algorithm. RESULTS: The resulting mean (and standard deviation) instrument-defined MID estimates were Germany, 0.083 (0.022); Indonesia, 0.093 (0.012); Ireland, 0.098 (0.023); Malaysia, 0.072 (0.010); Poland, 0.080 (0.030); Portugal, 0.080 (0.018); Taiwan, 0.101 (0.010); and the United States, 0.078 (0.014). CONCLUSIONS: These population preference-based MID estimates and accompanying evidence of how such values vary as a function of baseline index score can be used to aid interpretation of index score change. The marked consistency in the relationship between the calculated MID estimate and the range of the…

  21. 29
    top 3.4%
  22. 30
    top 3.5%

    Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group

    Kevin Marsh, Janine Astrid van Til, Elizabeth Molsen-David, Christin Juhnke, Natalia Hawken and 13 more

    52 citationsOpen access (PUBLIC-DOMAIN)doi:10.1016/j.jval.2019.11.009OpenAlex

    Show abstract

    OBJECTIVE: This study examines European decision makers' consideration and use of quantitative preference data. METHODS: The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions. RESULTS: Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value…

  23. 32
    top 3.7%

    Value of a QALY for France: A New Approach to Propose Acceptable Reference Values

    B. Téhard, B. Detournay, Isabelle Borget, Stéphane Roze, Gérard de Pouvourville

    49 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.04.001OpenAlex

    Show abstract

    OBJECTIVE: France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France. METHODS: We used the official French value of statistical life (VSL) of €3 million (USD 3.25 million), proposed in 2013 by the French General Commission on Strategy and Prediction. We first estimated the value of life-year (VoLY) by age category according to life expectancy and official discounts recommended for HEA in France. We then estimated a value of statistical QALY (VSQ) by weighting VoLYs with demographic data and French EQ-5D-3L tariffs. RESULTS: The estimated average…

  24. 33
    top 3.9%

    Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis

    Anna S. Wiksten, Neil Hawkins, Hans‐Peter Piepho, Sandro Gsteiger

    48 citationsOpen accessdoi:10.1016/j.jval.2020.03.010OpenAlex

  25. 35
    top 4.1%

    Improving Academic Biobank Value and Sustainability Through an Outputs Focus

    Amanda Rush, Daniel Robin Catchpoole, Rod Ling, Andrew Searles, Peter Hamilton Watson and 1 more

    47 citationsOpen accessdoi:10.1016/j.jval.2020.05.010OpenAlex

  26. 38
    top 4.4%
  27. 40
    top 4.7%

    Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease

    Ekkehard C. Beck, Johan Klint, Mohamed El Moctar Neine, Stéphanie Garcia, Kinga Meszaros

    43 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.09.004OpenAlex

    Show abstract

    OBJECTIVES: This cost-effectiveness analysis (CEA) of 4CMenB infant vaccination in England comprehensively considers the broad burden of serogroup B invasive meningococcal disease (MenB IMD), which has not been considered, or was only partially considered in previous CEAs. METHODS: A review of previous MenB vaccination CEAs was conducted to identify aspects considered in the evaluation of costs and health outcomes of the disease burden of MenB IMD. To inform the model structure and comprehensive analysis, the aspects were grouped into 5 categories. A stepwise analysis was conducted to analyze the impact of each category, and the more comprehensive consideration of disease burden, on the incremental cost-effectiveness ratio (ICER). RESULTS: MenB IMD incidence decreased by 46.0% in infants and children 0-4 years old within 5 years after introduction of the program. Stepwise inclusion of the 5 disease burden categories to a conventional narrow CEA setting reduced the ICER from £360 595 to £18 645-that is, considering the impact of all 5 categories, 4CMenB infant vaccination is…

  28. 41
    top 4.8%

    Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions

    Carol McLoughlin, Ilias Goranitis, Hareth Al‐Janabi

    43 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.01.015OpenAlex

    Show abstract

    OBJECTIVES: Carer quality-of-life (QoL) effects are recommended for inclusion in economic evaluations, but little is known about the relative performance of different types of QoL measures with carers. This study evaluated the validity and responsiveness of 3 care-related QoL measures (the Carer Experience Scale [CES], CarerQoL-7D, and ASCOT-Carer), 1 health-related QoL measure (the EQ-5D-5L), and 1 generic QoL measure (the ICECAP-A). METHODS: Validity and responsiveness were assessed in a UK sample of informal carers of adults with dementia, stroke, mental illness, or rheumatoid arthritis. A questionnaire containing the 5 QoL measures was posted to carers identified through the Family Resources Survey (N = 1004). Hypotheses regarding the anticipated associations between constructs related to the QoL of carers were tested to investigate construct validity and responsiveness. RESULTS: Each measure exhibited some level of construct validity. In general, larger effect sizes and stronger associations were detected for the ASCOT-Carer and ICECAP-A measures in the pooled sample and across…

  29. 42
    top 4.9%

    Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments

    Federico Augustovski, María Belizán, Luz Gibbons, Nora Reyes Puma, Elly A. Stolk and 2 more

    42 citationsOpen accessdoi:10.1016/j.jval.2020.05.004OpenAlex

  30. 44
    top 5.1%
  31. 45
    top 5.2%

    The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment

    Jason J. Ong, Richard De Abreu Lourenço, Deborah J. Street, Kirsty S. Smith, Muhammad Shahid Jamil and 12 more

    40 citationsOpen accessdoi:10.1016/j.jval.2020.04.1826OpenAlex

  32. 46
    top 5.4%

    Patient-Reported Morbidity Instruments: A Systematic Review

    Arvind Oemrawsingh, Nishwant S. Swami, José M Valderas, Jan Antonius Hazelzet, Andrea L. Pusic and 2 more

    40 citationsOpen accessdoi:10.1016/j.jval.2020.02.006OpenAlex

  33. 48
    top 5.6%

    Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting

    Thomas Sullivan, Nicholas R. Latimer, Jodi Gray, Michael Joseph Sorich, Amy B. Salter and 1 more

    40 citationsOpen accessdoi:10.1016/j.jval.2019.10.015OpenAlex

  34. 49
    top 5.7%

    An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom

    Jack Williams, Peter T. Vickerman, Sam T Douthwaite, Gaia Nebbia, Laura J Hunter and 3 more

    39 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.03.014OpenAlex

    Show abstract

    OBJECTIVES: The prevalence of hepatitis is high in emergency department (ED) attendees in the United Kingdom, with a prevalence of up to 2% for hepatitis B (HBV) HBsAg, and 2.9% for hepatitis C (HCV) RNA. The aim of this paper is to perform an economic evaluation of opt-out ED-based HCV and HBV testing. METHODS: A Markov model was developed to analyze the cost-effectiveness of opt-out HCV and HBV testing in EDs in the UK. The model used data from UK studies of ED testing to parameterize the HCV and HBV prevalence (1.4% HCV RNA, 0.84% HBsAg), test costs, and intervention effects (contact rates and linkage to care). For HCV, we used an antibody test cost of £3.64 and RNA test cost of £68.38, and assumed direct-acting antiviral treatment costs of £10 000. For HBV, we used a combined HBsAg and confirmatory test cost of £5.79. We also modeled the minimum prevalence of HCV (RNA-positive) and HBV (HBsAg) required to make ED testing cost-effective at a £20 000 willingness to pay per quality-adjusted life-year threshold. RESULTS: In the base case, ED testing was highly cost-effective, with…

  35. 50
    top 5.8%

    Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations

    Dalia Dawoud, Khaled Y. Soliman

    37 citationsOpen access (PUBLIC-DOMAIN)doi:10.1016/j.jval.2020.07.002OpenAlex

    Show abstract

    OBJECTIVE: To review published economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses. METHODS: We conducted a systematic review to identify economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses, including coronavirus disease 2019 (COVID-19). We searched Medline (EBSCOhost), EMBASE (Ovid), EconLit (Ovid), National Health Service Economic Evaluation Database (Ovid), and Health Technology Assessment (Ovid). The search was last rerun on July 5, 2020. Citation tracking and reference checking were used. Only full economic evaluations published as peer-reviewed articles in the last 10 years were included. Studies were quality assessed using the National Institute for Health and Care Excellence economic evaluation checklist. RESULTS: Overall, 782 records were identified, of which 14 studies met the inclusion criteria. The studies were mostly conducted in high-income countries. All were model-based. Seven (50%) were cost-utility analyses, 4 (28.6%) were cost-effectiveness analyses, 2 (14.3%) were…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to Value in Health with publication year 2020, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 16 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.